Go or no go? Bristol's first-in-class hopes
April should mark the approval of some of the biggest drugs of 2022, including Alnylam's vutrisiran, while TG will hope to be spared pain at the PI3K adcom.
Supernus and Pacira swoop while their targets are down
Two opportunistic buys today, of Adamas and Flexion, included a contingent value rights component.
Go or no go? The FDA plays hardball
April will see the US regulator examine Pfizer’s Jak in atopic dermatitis, and experts meet to discuss accelerated approvals in oncology.
First-quarter catalysts for the smaller players
Important data releases are on the cards for Rhythm, Wave and Supernus, among others.
Go or no go? Big decisions loom for Bristol and Sanofi
The FDA will have a busy November, with decisions due for Bristol, Sanofi and Y-mabs, among others.